Nasal potential measurements on the nasal floor and under the inferior turbinate: Does it matter?

Pediatric Pulmonology

Volumn 46, Issue 2, 2011, Pages 145-152

  Vermeulen, François ^a   Proesmans, Marijke ^a   Feyaerts, Nathalie ^a   De Boeck, Kris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cystic fibrosis; diagnosis

Indexed keywords

AMILORIDE; CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEASUREMENT; NASAL POTENTIAL MEASUREMENT; NOSE; PRIORITY JOURNAL; TURBINATE;

ADOLESCENT; ADULT; AMILORIDE; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MEMBRANE POTENTIALS; MIDDLE AGED; MUTATION; NASAL MUCOSA; SENSITIVITY AND SPECIFICITY; TURBINATES; YOUNG ADULT;

EID: 79251527503     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21333     Document Type: Article

References (21)

1. Rosenstein BJ, Cutting GR,. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589-595.
2. Goubau C, Wilschanski M, Skalicka V, Lebecque P, Southern KW, Sermet I, Munck A, Derichs N, Middleton PG, Hjelte L, Padoan R, Vasar M, De Boeck K,. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009; 64: 683-691.
3. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M,. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-635.
4. Knowles MR, Stutts MJ, Yankaskas JR, Gatzy JT, Boucher RC, Jr., Abnormal respiratory epithelial ion transport in cystic fibrosis. Clin Chest Med 1986; 7: 285-297.
5. Boucher RC,. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23: 146-158.
6. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC,. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981; 124: 484-490.
7. Knowles M, Gatzy J, Boucher R,. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981; 305: 1489-1495.
8. Alton EW, Hay JG, Munro C, Geddes DM,. Measurement of nasal potential difference in adult cystic fibrosis. Young's syndrome, and bronchiectasis. Thorax 1987; 42: 815-817.
9. Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM,. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990; 3: 922-926.
10. Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, Klar A, Ilani A, Kerem B, Kerem E,. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17: 1208-1215.
11. Wilson DC, Ellis L, Zielenski J, Corey M, Ip WF, Tsui LC, Tullis E, Knowles MR, Durie PR,. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. J Pediatr 1998; 132: 596-599.
12. Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram M, Picard E, Bdolah-Abram T, Wilschanski M,. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007; 132: 1219-1226.
13. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P,. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174: 787-794.
14. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M,. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727.
15. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E,. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-1441.
16. Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, Kelley TJ, Hilliard KA, Milgram LJ, Konstan MW, Weatherly MR, McCarty NA,. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002; 33: 142-150.
17. Schuler D, Sermet-Gaudelus I, Wilschanski M, Ballmann M, Dechaux M, Edelman A, Hug M, Leal T, Lebacq J, Lebecque P, Lenoir G, Stanke F, Wallemacq P, Tummler B, Knowles MR,. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004; 3: 151-155.
18. Knowles MR, Paradiso AM, Boucher RC,. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
19. Middleton PG, Geddes DM, Alton EW,. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994; 7: 2050-2056.
20. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
21. Zweig MH, Campbell G,. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.